中文(简体)
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)

Pregabalin in the Treatment of Essential Tremor

只有注册用户可以翻译文章
登陆注册
链接已保存到剪贴板
状态已完成
赞助商
Baylor College of Medicine
合作者
Pfizer

关键词

抽象

Pregabalin is approved for the treatment of nerve pain as well as an additional therapy in the treatment of seizures. In December 2004, Pfizer gained Food and Drug Administration (FDA) approval for use of pregabalin in nerve pain associated with diabetes and shingles; making it the first FDA-approved treatment for both of these nerve pain states.
Tremor is uncontrolled trembling in part of the body. Essential tremor (ET) is associated with purposeful movement(e.g., holding a glass to drink, shaving, writing and buttoning a shirt). It occurs most often in the hands and head and also may affect the arms, voice box (larynx), trunk, and legs. ET is caused by abnormalities in areas of the brain that control movement. It usually does not result in serious complications.
ET affects approximately 5 million people in the United States. Incidence is highest in people over the age of 60.
ET usually develops gradually during middle age or later in life. Symptoms may remain mild or become more severe over time. Stress, fatigue, anxiety, and hot or cold weather can worsen the disorder. Severe tremor may cause difficulty doing activities of daily living, such as:
- Brushing hair and teeth
- Holding a glass without spilling
- Performing self-care (e.g., getting dressed, shaving, putting on makeup)
- Using eating utensils
- Writing and drawing
The purpose of this study is to examine the tolerability and efficacy of Pregabalin in patients with ET .
In other words, can patients diagnosed with ET tolerate high dose of pregabalin? Will the pregabalin be considered as an efficient medicine in the treatment of ET?

日期

最后验证: 10/31/2015
首次提交: 12/27/2007
提交的预估入学人数: 03/25/2008
首次发布: 03/27/2008
上次提交的更新: 11/03/2015
最近更新发布: 11/05/2015
实际学习开始日期: 05/31/2006
预计主要完成日期: 11/30/2008
预计完成日期: 11/30/2008

状况或疾病

Essential Tremor

干预/治疗

Drug: 1

Drug: 2

相 4

手臂组

干预/治疗
Experimental: 1
Pregabalin 75 mg bid to a maximum dose of 300 mg bid
Drug: 1
75 mg bid to 300 mg bid based on per subject tolerability
Placebo Comparator: 2
Placebo to 4 capsules bid
Drug: 2
up to 4 capsules bid as tolerated

资格标准

有资格学习的年龄 18 Years 至 18 Years
有资格学习的性别All
接受健康志愿者
标准

Inclusion Criteria:

1. Subjects must be between the ages of 18 and 80 inclusive.

2. Each subject must have current manifestations of ET symptoms based on the Tremor Investigational Group (TRIG) criteria for definite or probable ET: - Moderate or severe tremor in head or arms for at least 3 years duration. - No present causes of enhanced physiologic tremor. - No recent exposure to tremorogenic drugs or drug withdrawal states. - No direct or indirect trauma to the nervous system within 3 months preceding the onset of tremor. - No historic or clinical evidence of psychogenic tremor origin.

3. Subjects with a history of seizures are eligible.

4. Subjects must be in generally good health as evidenced by previous medical history and clinical examination.

5. Patients will be allowed to take Beta-blockers but will not be allowed to take any other medication for tremor (primidone, topiramate, benzodiazepines, etc.) An evening dose of a benzodiazepine to improve sleep is acceptable. They must have been on a stable dose of any existing beta-blocker for 4 weeks prior to entry into the study and will not be allowed to change the dose of that medication throughout the controlled portion of the study. Any medication discontinued during screening in order to comply with these criteria must be stopped for 5 half-lives prior to study initiation.

6. Subjects must be accessible by telephone.

7. If the subject is a female of childbearing age, she must have had a hysterectomy, tubal ligation, otherwise be incapable of pregnancy, or have practiced one of the following methods of contraception for at least one month prior to study entry (or a negative urine pregnancy test within one week of study entry): - Hormonal contraceptives - Spermicide and barrier - Intrauterine device - Partner sterility

8. Prior to participation in this study, each subject must sign an informed consent.

Exclusion Criteria:

1. Patients do not meet TRIG criteria for probable ET.

2. Subjects who are not able to abstain from alcohol for 24 hours prior to each evaluation.

3. Patients who can not maintain an identical dose of any medicine that may affect tremor during their entire study involvement.

4. Subjects who have exhibited any psychotic symptomatology.

5. Subjects who have known renal deficiencies.

6. Subjects who have been intolerant of pregabalin in the past

7. Prior surgical treatment for tremor.

8. Patients currently taking more than a single drug for ET.

9. Patients taking anti-seizure medications.

10. Breast feeding or pregnant females.

结果

主要结果指标

1. Change from baseline in the overall TRS score obtained at the final evaluation (end of study). The overall TRS score will be derived from the three TRS subcecals giving a maximum score of 84 which will be converted to a 100 point scale. [baseline to completion]

次要成果指标

1. Nonparametric tests will be employed and exact p (2 tailed) values computed for the categorical dependent variables. [baseline to completion]

加入我们的脸书专页

科学支持的最完整的草药数据库

  • 支持55种语言
  • 科学支持的草药疗法
  • 通过图像识别草药
  • 交互式GPS地图-在位置标记草药(即将推出)
  • 阅读与您的搜索相关的科学出版物
  • 通过药效搜索药草
  • 组织您的兴趣并及时了解新闻研究,临床试验和专利

输入症状或疾病,并阅读可能有用的草药,输入草药并查看所使用的疾病和症状。
*所有信息均基于已发表的科学研究

Google Play badgeApp Store badge